Related Experiment Video
Updated: Jul 6, 2026
10:58
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
Glioblastoma in adults
Alba A Brandes1, Alicia Tosoni, Enrico Franceschi
1Department of Medical Oncology, Bellaria-Maggiore Hospital, Azienda ASL, Bologna, Italy. alba.brandes@yahoo.it
Critical Reviews in Oncology/Hematology
|April 9, 2008
Summary
Glioblastoma (GBM) is a severe brain tumor with poor prognosis. Standard treatment involves surgery, radiation, and temozolomide (TMZ), with nitrosourea or TMZ re-challenge for recurrence.
Area of Science:
- Neuro-oncology
- Cancer Research
- Clinical Medicine
Background:
- Glioblastoma (GBM) is the most aggressive astrocytic tumor, characterized by a poor prognosis.
- Key prognostic factors include age, performance status, mini-mental status, MGMT promoter methylation, and extent of surgical resection.
Purpose of the Study:
- To outline the standard management and therapeutic options for glioblastoma.
- To discuss treatment strategies for recurrent or progressive glioblastoma.
Main Methods:
- Surgical resection is the primary therapeutic approach.
- Standard postoperative treatment involves concomitant chemoradiation with temozolomide (TMZ).
- Radiotherapy is delivered at 60Gy to a defined target volume, with concurrent and adjuvant TMZ cycles.
Main Results:
- Complete surgical resection is often unachievable due to the infiltrative nature of GBM, leading to inevitable relapse.
- Postoperative chemoradiation with TMZ is the established standard of care.
- Recurrent GBM management includes nitrosourea-based chemotherapy or temozolomide re-challenge.
Conclusions:
- Despite maximal therapeutic efforts, glioblastoma recurrence is common.
- Current treatment paradigms focus on optimizing surgical resection, standard chemoradiation, and managing disease progression.
- Further research into novel therapeutic strategies for glioblastoma is warranted.
